Causes of chest pain
Higher doses of prednisone are rarely necessary unless there is a life-threatening systemic disease and if used for prolonged periods, will lead to unacceptable steroid toxicity. causes of chest pain Abdominal pain lower left. Although a few patients can tolerate every other day dosing of corticosteroids which may reduce side effects, most require corticosteroids daily to avoid symptoms. Once a day dosing of prednisone is associated with fewer side effects than the equivalent dose given bid or tid. Repetitive short courses of high-dose corticosteroids, intermittent intramuscular injections, adrenocorticotropic hormone injections, and the use of corticosteroids as the sole therapeutic agent are all to be avoided. causes of chest pain Spleen pain. Intra-articular corticosteroids (e. g. , 40mg of triamcinolone in a knee, 20mg in a shoulder, or 2mg in a finger) are effective for controlling a local flare in one or two joints without changing the overall drug regimen. causes of chest pain Arthritis-clinics. (top of section) Disease Modifying Anti-rheumatic Drugs (Agents with Delayed Onset of Action) Although both NSAIDs and DMARD agents improve symptoms of active rheumatoid arthritis, DMARD agents may alter the disease course and improve long term outcomes-- although it has been difficult to prove conclusively due to disagreements on study design and the necessity of long term patient follow-up. In any case DMARDs have an effect upon rheumatoid arthritis that is different and more delayed in onset than either NSAIDs or corticosteroids. Once persistent disease activity (chronic synovitis) is established, a DMARD agent should be considered. The development of erosions or joint space narrowing on x-rays of the involved joints is a clear indication for DMARD therapy, however one should not wait for x-ray changes to occur. The currently available drugs include: leflunomide soluble interleukin-1 (IL-1) receptor therapy tumor necrosis factor inhibitors methotrexate hydroxychloroquine and sulfasalazine intramuscular gold cytotoxic agents (cyclosporine A, azathioprine, and cyclophosphamide) Leflunomide (AravaT) Leflunomide was approved by the FDA and became available as a new DMARD agent for rheumatoid arthritis in October 1998. In clinical trials, its efficacy was similar to that of methotrexate and will represent a viable alternative to patients who have failed or were intolerant to methotrexate. The most recent clinical trial data were presented at the 1999 American College of Rheumatology meetings(see ACR Highlights). In a yearlong study, leflunomide was superior to methotrexate in preventing x-ray joint erosions, but this finding will need to be confirmed with additional studies.
Causes of chest pain
Relief || Diet-tips-for-arthritis || Cats-arthritis || Arthritis-hip-alternative-cures-non-surgical